The financials
AbCellera Biologics Inc. by the numbers
AbCellera Biologics Inc. (ABCL) reported revenue of $8.3M in Q1 2026 (quarter ended Mar 31, 2026), up 96% from the same quarter a year earlier. That came with net loss of $43M. For the full year FY2025, revenue was $75M (+161% year on year) and net income −$146M. Its largest product in Jun 2026 was Research Fees at $3.9M, 96% of the disclosed total, well ahead of Licensing And Royalty at 3.7%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $8.3M | $4.2M | +96% |
| Operating income | −$58M | −$63M | n/a |
| Net income | −$43M | −$46M | n/a |
| Diluted EPS | −$0.14 | −$0.15 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Research Fees | $3.9M | 96% |
| Licensing And Royalty | $149K | 3.7% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $4.0M (-51%)
Research Fees grew -41% year on yearLicensing And Royalty -99% year on year
Segment Latestquarter on quarteryear on year
- Research Fees$3.9M$3.9MQoQ -52%year on year -41%-52%-41%
- Licensing And Royalty$149.0K$149.0KQoQ -22%year on year -99%-22%-99%